$7.25B Roundup Settlement Proposed to End Litigation Over Allegations Weed Killer Causes Non-Hodgkin Lymphoma

New to ClassAction.org? Read our Newswire Disclaimer

Bayer AG subsidiary Monsanto has agreed to a $7.25 billion settlement that, if approved by the court, would resolve current and future allegations that exposure to Roundup herbicide can cause non-Hodgkin lymphoma.

Don’t miss out on class action settlement news like this. Sign up for ClassAction.org’s free weekly newsletter.

The proposed nationwide Roundup settlement, filed on February 17, 2026, awaits preliminary approval from the court. The massive deal, filed in St. Louis, Missouri circuit court, would cover individuals who were exposed to Roundup before February 17, 2026 and either received a medical diagnosis of non-Hodgkin lymphoma (NHL) or, in the future, receive a medical diagnosis of NHL before the end of a 16-year period following final approval.

According to a statement released by Bayer AG, the proposed $7.25 billion Roundup settlement would provide ongoing cash payments through a long-term claims program, funded over 21 years through declining annual payments from Monsanto.

ClassAction.org will update this page once the proposed Roundup settlement receives preliminary approval.

Bayer AG’s statement notes that the proposed class action settlement is intended to avoid the need to continue litigating current and future Roundup personal injury lawsuits. 

Roundup has been the subject of years of mass tort litigation over allegations that glyphosate, the primary ingredient in the common garden herbicide, causes non-Hodgkin lymphoma, a type of cancer that develops in the body’s lymphatic system. The proposed Roundup class action settlement would replace a previous short-term class settlement filed by Monsanto in 2020.

Did you know that some class action settlements require no proof to submit a claim? Check out the latest top class action settlements.